Treatment of Stage IVA Hepatocellular Carcinoma

Treatment of Stage IVA Hepatocellular Carcinoma Should

Main Outcome Measures: Intraoperative data, recurrence, and long-term survival rates were analyzed. Results: Postoperative mortality and morbidity were 5% and 30%, respectively. The median number of resected tumors per patient was 3, and the median diameter of the largest tumor was 60 mm. With a median follow-up of 23 months, 14 patients (70%) developed recurrence. Treatment of recurrence was p...

Treatment of stage IVA hepatocellular carcinoma: should we reappraise the role of surgery?

HYPOTHESIS A subset of patients with stage IVA hepatocellular carcinoma (HCC) and preserved liver function may benefit from hepatic resection. DESIGN Retrospective review of a prospectively collected database. SETTING An academic tertiary care hepatobiliary unit. PATIENTS Twenty patients who underwent surgical treatment for stage IVA HCC between July 1998 and October 2004 were identified ...

Preclinical studies of 166Ho-chitosan for treatment of hepatocellular carcinoma

Introduction: Recently, due to the special characteristics of 166Ho and chitosan, 166Ho-chitosan complex was developed for treatment of tumors such as hepatocellular carcinoma. This complex has been lately prepared with high radiochemical purity in our lab. The preclinical studies of the complex however should be performed to evaluate the tracer concentration in target and...

Hepatocellular Carcinoma in Sheep

Treatment of hepatocellular carcinoma.

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world, and is the third highest cause of cancer-related mortality. HCC usually develops in patients with chronic liver disease, particularly in those who also have cirrhosis. The possibility of curative treatment depends on both the stage of tumor and liver function. Effective treatments for HCC include percutaneous ablation,...